News | Proton Therapy | April 25, 2019

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment

Patients invited to participate in Proton Collaborative Group (PCG) Registry and clinical trial of partial breast irradiation in early-stage breast cancer

California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment

April 25, 2019 — California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast cancer treatment research involving its noninvasive, targeted proton therapy. Current California Protons patients as of Feb. 4, 2019, are invited to enroll in the Proton Collaborative Group (PCG) Registry of more than 13,000 patients. Separately, the PCG BRE007-12 Partial Breast Irradiation in early-stage breast cancer clinical trial will enroll around five to eight females per year.

The PCG Registry has been in existence since 2010. It is a prospective tracking study that allows for the collection and analysis of patient information to evaluate the disease process and treatment-related outcomes, thus defining strengths and weaknesses of proton radiation therapy. Qualified patients are invited to enroll in person at their first physician visit during treatment.

The primary objective of the PCG BRE007-12 Partial Breast Irradiation study is to determine freedom from ipsilateral breast recurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at three years post-treatment. One of the goals of this study is to determine whether or not limiting radiation to just a portion of the breast is as effective as the traditional treatment of the entire breast. A number of trials have suggested that this “partial breast” approach is every bit as effective as treating the entire breast and may also be less toxic. Performing such partial breast treatments with protons can help to further reduce toxicity by taking advantage of the protons’ ability to be precisely conformed to the target area without giving “spillover” radiation to surrounding healthy tissue such as the lung and heart.

PCG has partnered with 11 proton treatment centers in the U.S., and the data has been used in close to 50 scientific manuscripts, posters and academic presentations to date. PCG research has been presented at 20 medical conferences and has been published in a number of peer-reviewed medical journals.

Both the Patient Registry and the Partial Breast Irradiation Trial are Institutional Review Board (IRB)-approved. These breast cancer trials supplement California Protons Cancer Therapy Center’s ongoing research projects with the University of California San Diego (UCSD) and the Radiation Therapy Oncology Group (RTOG) Foundation 3510 Phase III randomized trial of proton versus photon therapy for patients with nonmetastatic breast cancer receiving comprehensive nodal radiation.

Watch the VIDEO: Whole Versus Partial Radiotherapy for Breast Cancer

For more information: www.californiaprotons.com

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...